Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 452-459

  Poynard, Thierry ^a   Bruix, Jordi ^b   Schiff, Eugene R ^c   Diago, Moises ^d   Berg, Thomas ^e   Moreno Otero, Ricardo ^f   Lyra, Andre C ^g   Carrilho, Flair ^h   Griffel, Louis H ⁱ   Boparai, Navdeep ^a,i   Jiang, Ruiyun ⁱ   Burroughs, Margaret ⁱ   Brass, Clifford A ⁱ   Albrecht, Janice K ⁱ  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biomarkers; Fibrosis; FibroTest; Hepatitis C; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER FIBROSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METAVIR FIBROSIS SCORE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INFLAMMATION; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84874118665     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.11.001     Document Type: Article

References (22)

1. T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg, and S. Flamm Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
2. J. Bruix, T. Poynard, M. Colombo, E. Schiff, K. Burak, and E.J. Heathcote Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 2011 1990 1999
3. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, and E.C. Wright Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
4. Afdhal N, Levine R, Brown R, Jr., Freilich B, O'Brien M, Brass C. Colchicine versus peg-interferon alfa 2b long-term therapy: results of the 4-year COPILOT trial [oral presentation]. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver, April 23-27, 2008, Italy: Milan.
5. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, and Z. Goodman Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
6. P. Halfon, M. Munteanu, and T. Poynard FibroTest-ActiTest as a non-invasive marker of liver fibrosis Gastroenterol Clin Biol 32 2008 22 39
7. T. Poynard, F. Imbert-Bismut, M. Munteanu, D. Messous, R.P. Myers, and D. Thabut Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C Compar Hepatol 3 2004 8
8. F. Imbert-Bismut, D. Messous, A. Raoult, T. Poynard, J.J. Bertrand, and P.A. Marie Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of Fibrotest and Actitest Ann Biol Clin (Paris) 63 2005 305 313
9. F. Imbert-Bismut, D. Messous, V. Thibault, R.B. Myers, A. Piton, and D. Thabut Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors Clin Chem Lab Med 42 2004 323 333
10. T. Poynard, M. Munteanu, M. Colombo, J. Bruix, E. Schiff, and R. Terg FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(3) program J Hepatol 54 2011 227 235
11. J.L. Dienstag, M.G. Ghany, T.R. Morgan, A.M. Di Bisceglie, H.L. Bonkovsky, and H.Y. Kim A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C Hepatology 54 2011 396 405
12. E.L. Ellis, and D.A. Mann Clinical evidence for the regression of liver fibrosis J Hepatol 56 2012 1171 1180
13. K. Patel, M. Friedrich-Rust, Y. Lurie, M. Grigorescu, C. Stanciu, and C.M. Lee FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus World J Gastroenterol 17 2011 4581 4589
14. B. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
15. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, and N.H. Afdhal Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
16. D.S. Manning, and N.H. Afdhal Diagnosis and quantitation of fibrosis Gastroenterology 134 2008 1670 1681
17. T. Poynard, Y. Ngo, M. Munteanu, D. Thabut, J. Massard, and J. Moussalli Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies Antiviral Ther 15 2010 617 631
18. N. Snyder, L. Gajula, S.-Y. Xiao, J. Grady, B. Luxon, and D.T.-Y. Lau APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C J Clin Gastroenterol 40 2006 535 542
19. T. Poynard, M. Munteanu, O. Deckmyn, Y. Ngo, F. Drane, and J.M. Castille Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population J Hepatol 57 2012 541 548
20. Y. Ngo, M. Munteanu, D. Messous, F. Charlotte, F. Imbert-Bismut, and D. Thabut A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C Clin Chem 52 2006 1887 1896
21. J. Vergniol, J. Foucher, E. Terrebonne, P.H. Bernard, B.B. Le, and W. Merrouche Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C Gastroenterology 140 2011 1970 1979
22. T. Poynard, G. Lenaour, J.C. Vaillant, F. Capron, M. Munteanu, and D. Eyraud Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis Clin Gastroenterol Hepatol 10 2012 657 663